857465-38-4

Basic information

• Product Name: 3-(nitrooxymethyl)benzyl alcohol
• Synonyms: 3-(nitrooxymethyl)benzyl alcohol
• CAS NO: 857465-38-4
• Molecular Weight: 183.164
• Mol File: 857465-38-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(nitrooxymethyl)benzyl alcohol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(nitrooxymethyl)benzyl alcohol(857465-38-4)
• EPA Substance Registry System: 3-(nitrooxymethyl)benzyl alcohol(857465-38-4)

Safety Data

• Hazardous Substances Data: 857465-38-4(Hazardous Substances Data)

Upstream product

• 175464-51-4 3-(chloromethyl)-phenyl methanol 
• 626-18-6 1,3-dimethanol benzene 

Downstream Products

• 857464-18-7 {3-[(nitrooxy)methyl]phenyl}methyl 2-oxopropanoate 

Relevant articles and documents

Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use

The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one c

New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: Design, synthesis, and biopharmacological properties

In a preliminary work, we reported two NO-sartans, possessing the characteristics of an AT1 antagonist and a "slow NO donor", obtained by adding NO-donor side chains to losartan 1. The NO release from an NO-sartan should be modulated in order to strengthen the antihypertensive activity of the native drug and to ensure additional effects, such as the antiplatelet and anti-ischemic ones. To obtain a collection of proto-typical NO-sartans, showing different rates of NO release, new NO-donor moieties have been linked to 1 or its active metabolite 2 (EXP 3174). Almost all the synthesized compounds exhibited both AT1-antagonist and NO-mediated vasorelaxing properties, with a wide range of NO-releasing rates. Further pharmacological investigation on compound 4a showed that it possessed antihypertensive and cardiac antihypertrophic effects similar to those of the reference AT1-blocking or ACE-inhibiting drugs. Furthermore, the additional anti-ischemic cardio-protective properties and antiplatelet effects of 4a have been preliminarily investigated.